Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 3, 2013, Pages 690-696

  Charpentier, Charlotte ^a   Joly, Véronique ^a   Larrouy, Lucile ^a   Fagard, Catherine ^b,c   Visseaux, Benoit ^a   de Verdiére, Nathalie Colin ^d   Raffi, François ^e   Yeni, Patrick ^a   Descamps, Diane ^a  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e HÔTEL DIEU   (France)

Author keywords

Enfuvirtide; HIV DNA; Resistance; Switch; Tropism

Indexed keywords

ENFUVIRTIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA; VIRUS RNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; COPY NUMBER VARIATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VIRAL TROPISM; VIRUS MUTATION;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; MUTATION, MISSENSE; PEPTIDE FRAGMENTS; VIRAL TROPISM; YOUNG ADULT;

EID: 84873597968     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks455     Document Type: Article

References (16)

1. Joly V, Fagard C, Descamps D et al. Intensification of HAART through the addition of enfuvirtide (ENFUVIRTIDE) in naïve HIV-infected patients with severe immunosuppression does not improve immunological response: results of a prospective randomised multicenter trial (APOLLO-ANRS 130). In: Abstracts of the Seventeenth Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2010. Abstract 282.
2. Derdeyn CA, Decker JM, Sfakianos JN et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitor targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 2001; 75: 8605-14.
3. Melby T, DeSpirito M, DeMasi R et al. HIV-1 coreceptor use in tripleclass treatment-experienced patients: baseline prevalence, correlates and relationship to enfuvirtide response. J Infect Dis 2006; 194: 238-46.
4. Bennett DE, Camacho RJ, Otelea D et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4: e4724.
5. Descamps D, Chaix ML, Montes B et al. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. J Antimicrob Chemother 2010; 65: 2620-7.
6. Wittkop L, Günthard HF, de Wolf F et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11: 363-71.
7. Metzner KJ, Allers K, Rauch P et al. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients. AIDS 2007; 21: 703-11.
8. Molina JM, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372: 646-55.
9. Riddler SA, Haubrich R, DiRienzo AG et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 2095-106.
10. Wilkin TJ, Su Z, Kuritzkes DR et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinicaltrial of a CCR5 inhibitor: AIDS Clinical Trial Arm A5211. Clin Infect Dis 2007; 44: 591-5.
11. Brumme ZL, Goodrich J, Mayer HB et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192: 466-74.
12. Paar C, Geit M, Stekel H et al. Genotypic prediction of human immunodeficiency virus type 1 tropism by use of plasma and peripheral blood mononuclear cells in the routine clinical laboratory. J Clin Microbiol 2011; 49: 2697-9.
13. Parisi SG, Andreoni C, Sarmati L et al. HIV coreceptor tropism in paired plasma, peripheral blood mononuclear cell, and cerebrospinal fluid isolates from antiretroviral-nai{dotless}̈ve subjects. J Clin Microbiol 2011; 49: 1441-5.
14. Saracino A, Monno L, Cibelli DC et al. Co-receptor switch during HAART is independent of virological success. J Med Virol 2009; 81: 2036-44.
15. Seclén E, Soriano V, GonzálezMMet al. Impact of baseline HIV-1 tropism on viral response and CD4 cell count gains in HIV-infected patients receiving first-line antiretroviral therapy. J Infect Dis 2011; 204: 139-44.
16. Waters L, Mandalia S, Randell P et al. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 2008; 46: 1617-23.